As regulations evolve and PFAS analysis expands beyond traditional water testing, laboratories are adapting to new challenges across environmental, food and industrial sectors.Laboratories around the world are facing a new reality for <a target="_blank" rel="noopener noreferrer" href="https://www.thermofisher.com/content/lifetech/global/en/home/industrial/environmental/environmental-contaminant-analysis/emerging-contaminants/pfas-testing.html">PFAS analysis</a>. Expanding regulations, growing lists of compounds of concern, and increasing demand for analysis across environmental, food and industrial sectors mean many laboratories are being asked to do more than ever before.While these changes are global, Europe continues to play an important role in shaping the regulatory landscape. Since January 2026, EU Member States have been required to monitor PFAS levels in drinking water and ensure they remain within EU limits. Regulatory attention is also extending beyond drinking water to surface and groundwater, soil, packaging and industrial emissions, as outlined in the <a target="_blank" rel="noopener noreferrer" href="https://environment.ec.europa.eu/topics/chemicals/pfas-pollution_en">European Commission’s overview of PFAS pollution and EU action</a>.Although requirements differ by region, the direction is clear: laboratories are facing analytical questions involving more compounds and a wider range of matrices. For scientists looking to keep pace, our <a target="_blank" rel="noopener noreferrer" href="https://gateway.on24.com/wcc/eh/4080611/category/139628/pfas-testing?partnerref=E.25CMD.EL102.26305.01">PFAS resources</a> bring together webinars, application notes and expert insights across environmental, food and industrial testing.<h5>PFAS analysis is no longer defined by a single matrix or a single workflow.</h5><h3>PFAS analysis is expanding</h3>For many laboratories, PFAS analysis began with drinking water. Today, the scope has expanded considerably.Laboratories are increasingly working across drinking water, groundwater, surface water and wastewater, as well as food and food contact materials, cosmetics and personal care products, environmental samples, and industrial and consumer products.Each matrix presents different analytical challenges. Water analysis can require trace-level quantification, while complex food and consumer-product matrices may require different sample preparation or broader screening approaches. Techniques such as total organic fluorine (TOF) analysis can also provide a complementary perspective to targeted PFAS measurements.This diversity means there is no single analytical approach that answers every PFAS question.<h5>As PFAS analysis expands beyond drinking water, laboratories need approaches that can adapt to diverse sample types and evolving regulatory expectations.</h5><h3>Learning from the scientific community</h3>As laboratories respond to these changing analytical demands, many are exploring new approaches to longstanding challenges such as sample preparation.One example comes from Severn Trent Laboratories (Bridgend, UK), which implemented a PFAS workflow using Dispersive Liquid–Liquid Micro Extraction (DLLME). The approach provides an alternative to traditional solid phase extraction and can help reduce sample handling and solvent consumption.Laboratories interested in the approach can explore more information on <a target="_blank" rel="noopener noreferrer" href="https://www.thermofisher.com/content/lifetech/global/en/home/industrial/environmental/efox-analytical-solutions-platform/workflows.html">DLLME and PFAS workflows</a>.<h3>Watch the webinar</h3><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_2aeaa52248.jpg" alt="Thermo Fisher Scientific: PFAS Analysis Beyond Water: Meeting the Challenges of Environmental, Food and Industrial Testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_2aeaa52248.jpg 245w," sizes="100vw" width="800" height="347"><h4>Severn Trent / PFAS webinar</h4>EFOX approach for environmental workflows: PFAS &amp; emerging contaminantsHear more about this approach and explore wider developments in PFAS and emerging contaminant analysis.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/webinar/6542">Watch on demand</a></h4></blockquote><h3>The changing PFAS landscape</h3>The changing analytical landscape extends well beyond sample preparation. Laboratories are simultaneously navigating evolving regulations, growing lists of compounds of interest, greater scrutiny of food and industrial materials, and increasing interest in broader screening approaches.Europe illustrates how these trends are converging. Alongside drinking-water requirements, EU action extends to industrial emissions and food-contact packaging. The Industrial Emissions Directive imposes stricter monitoring of PFAS emissions, with reporting requirements for PFOA, PFHxS and their salts from 2028. From August 2026, EU rules also ban food-contact packaging containing PFAS above specified concentration limits, as detailed in the <a target="_blank" rel="noopener noreferrer" href="https://environment.ec.europa.eu/topics/chemicals/pfas-pollution_en">European Commission’s overview of PFAS pollution and EU action</a>.Changes are also underway for Europe’s surface water and groundwater. Updated pollutant lists that entered into force in May 2026 include certain PFAS, including TFA, among substances to be monitored more closely and subject to stricter controls under the <a target="_blank" rel="noopener noreferrer" href="https://environment.ec.europa.eu/topics/water/water-framework-directive_en">EU Water Framework Directive.</a>The European picture also demonstrates why PFAS is no longer solely an environmental-water issue. PFAS have been widely used in products including food packaging, textiles, lubricants and batteries, while industrial activities that produce or use PFAS can contribute to environmental releases.Globally, regulatory requirements vary, but the analytical challenge is similar: laboratories need the flexibility to respond as both the compounds of interest and the matrices under investigation change.<h3>PFAS analysis across different sample types</h3>Different matrices raise different analytical questions—from selecting an appropriate sample preparation strategy to deciding between targeted quantification and broader screening approaches.<h4>Environmental and water PFAS analysis</h4><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_2_3ef68ae44e.jpg" alt="Thermo Fisher Scientific: PFAS Analysis Beyond Water: Meeting the Challenges of Environmental, Food and Industrial Testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_2_3ef68ae44e.jpg 245w," sizes="100vw" width="768" height="439">Explore analytical approaches for drinking water, groundwater, surface water and wastewater, including automated sample preparation and multi-matrix PFAS quantification.<ul><li><a target="_blank" rel="noopener noreferrer" href="https://www.thermofisher.com/content/lifetech/global/en/home/industrial/environmental/efox-analytical-solutions-platform/workflows.html">Automated DLLME for environmental PFAS analysis</a></li><li>Resource: <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/ab_004180_efs_orbitrap_exploris_efox_ab004180_em_en_932cc99eb4.pdf">Quantification of 61 PFAS across drinking water, groundwater, surface water and wastewater</a></li></ul><h4>Food and food contact materials PFAS analysis</h4><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_3_eb783dd0d3.jpg" alt="Thermo Fisher Scientific: PFAS Analysis Beyond Water: Meeting the Challenges of Environmental, Food and Industrial Testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_3_eb783dd0d3.jpg 245w," sizes="100vw" width="768" height="433">Explore PFAS analysis in food and food-contact materials, including total organic fluorine (TOF) screening and evolving approaches to investigating fluorinated compounds in packaging.<ul><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/article/5894">Enhancing PFAS analysis in food contact materials using combustion ion chromatography</a></li></ul><h4>Cosmetics / industrial PFAS analysis</h4><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_4_99a5bfea7e.jpg" alt="Thermo Fisher Scientific: PFAS Analysis Beyond Water: Meeting the Challenges of Environmental, Food and Industrial Testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_4_99a5bfea7e.jpg 245w," sizes="100vw" width="768" height="432">Explore approaches for investigating PFAS and total organic fluorine in complex matrices such as cosmetics and other consumer or industrial materials.<ul><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/an_004403_ic_cic_industrial_an004403_na_en_3c2419b88b.pdf">Total PFAS content in cosmetics using combustion ion chromatography</a></li></ul><blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://gateway.on24.com/wcc/eh/4080611/category/139628/pfas-testing?partnerref=E.25CMD.EL102.26305.01">Explore all PFAS resources</a></h4></blockquote><h3>Learn from experts</h3>As PFAS science and regulation continue to evolve, knowledge sharing across the scientific community is becoming increasingly valuable.<h4>Live from the Lab: Solutions for Environmental and Food Contaminant Analysis 2026</h4><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_5_3afde1ec49.jpg" alt="Thermo Fisher Scientific - PFAS Analysis Beyond Water - Meeting the Challenges of Environmental, Food and Industrial Testing 5.jpg" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_PFAS_Analysis_Beyond_Water_Meeting_the_Challenges_of_Environmental_Food_and_Industrial_Testing_5_3afde1ec49.jpg 245w," sizes="100vw" width="768" height="402">Join scientists from industry and academia to explore developments in environmental and food contaminant analysis. PFAS-focused discussions include regulatory trends, drinking water analysis, food-contact materials, workflow optimisation, source differentiation, and untargeted screening. Register to join us online or in person at one of our satellite events across Europe.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://gateway.on24.com/wcc/eh/4080611/category/150288/lftl-event-environmental-and-food-contaminant-testing?partnerref=E.25CMD.EL102.26305.01">Register here: Live from the Lab: Solutions for Environmental and Food Contaminant Testing</a></h4></blockquote><h3>Looking ahead</h3>PFAS analysis is unlikely to become simpler. As regulations evolve and new areas of testing emerge, laboratories will continue to face broader analytical questions across environmental, food and industrial testing.Preparing for the future isn’t about predicting every regulatory change. It’s about developing the knowledge and flexibility to respond as new compounds, matrices and analytical questions emerge.How is your laboratory preparing for the next phase of PFAS analysis? Whether you’re responding to new regulations, expanding into different matrices or evaluating new analytical approaches, staying connected to developments across the scientific community can help you prepare for what’s next.<blockquote>Visit us on&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/showcase/72003132/admin/dashboard/">LinkedIn:</a>&nbsp;#PFAS #PFASAnalysis #EnvironmentalTesting #FoodSafety</blockquote>

PFAS Analysis Beyond Water: Meeting the Challenges of Environmental, Food and Industrial Testing

Wiley, a global leader in authoritative content and research intelligence, today announced the launch of its spectral analysis application programming interface (API) portfolio, providing users with a new, faster way to access its trusted spectral data, analytical algorithms, and predictive models—within their own workflows.Wiley has one of the most comprehensive and trusted collections of scientific reference databases in the world, relied upon as a gold standard for identifying unknown chemical compounds by laboratories, instrument vendors, and software platforms across pharmaceuticals, forensics, environmental science, chemicals, food, materials, and other fields. The new portfolio extends the data and tools into modern, API-driven environments—allowing users to integrate high-quality spectral intelligence directly into their own systems and workflows.As sample volumes grow and lab workflows become more automated and software-driven, identifying and verifying compounds quickly and reliably becomes even more critical. The new API portfolio meets that need directly, giving labs and platforms a faster way to complete the process, whether catching a quality issue on a production line or identifying an unknown compound in the field. The result is less manual effort, faster analysis, and more confidence in the answer.The launch builds on Wiley's mission to transform knowledge into actionable intelligence for corporate and academic researchers around the world."Speed matters when you're trying to identify an unknown substance; a delayed analysis can mean an assembly line sitting idle or a forensic lab holding up a case,” said Armughan Rafat, Wiley senior vice president and chief AI and data services officer. “We've spent decades building the reference data this industry trusts. Now, by making that spectral data and analytical intelligence available through APIs, we're setting the standard for how labs and vendors turn unknowns into answers faster and at scale."<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Wiley_API_spectral_search_5bfcb1dd9b.png" alt="Wiley: spectral analysis API" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Wiley_API_spectral_search_5bfcb1dd9b.png 128w," sizes="100vw" width="802" height="977"><h5>The API portfolio launches with four core capabilities:</h5><ul><li>Spectral Database Search API – Query Wiley’s comprehensive reference collections for rapid compound identification.</li><li>Spectrum-Structure Validation API – Confirm proposed chemical structures against experimental spectral data.</li><li>Compound Classification API – Classify unknown substances, including drugs, based on compound class.</li><li>Spectra Prediction API – Generate predicted spectra to support research, method development, and validation.</li></ul>Unlike fragmented in-house databases or instrument-specific solutions, these APIs offer a continuously curated, vendor-neutral foundation that supports multi-technique workflows, regulatory compliance, and cross-platform interoperability. As a result, laboratories can increase throughput, minimize downtime, and protect the value of the instrumentation and data in which they've already invested.<h4>Spectral Databases &amp; APIs</h4>Spectral databases contain unique molecular “fingerprints” of substances captured through analytical techniques such as infrared (IR), mass spectrometry (MS), nuclear magnetic resonance (NMR), and Raman spectroscopy. By comparing experimental spectra against validated reference data, researchers can accurately identify unknown compounds across a wide range of applications.An API is a common way for computer systems, from lab instruments to software platforms, to request information from one another and get an answer back automatically.<blockquote>For more information about the Wiley spectral analysis API portfolio, please <a target="_blank" rel="noopener noreferrer" href="https://sciencesolutions.wiley.com/spectral-analysis-apis/">visit this website</a></blockquote><h4>About Wiley</h4>Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&amp;D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning.&nbsp;

Wiley Launches Its First Spectral Analysis API Portfolio

ISC 2026 - Day 5

Article

Product

Events

Environment

Software

PFAS 

A unique company dedicated to serving science helping our customers drive productivity and accelerate results. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Thermo Fisher Scientific

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

For over 200 years we have been helping people and organizations develop the skills and knowledge they need to succeed.
We develop digital education, learning, assessment, and certification solutions to help universities, businesses, and individuals move between education and employment and achieve their ambitions.

Wiley

Follistatin Analysis

Targeted HPLC analysis of follistatin in lyophilised vials and raw API powders, confirming identity and determining the amount of the compound.

The Follistatin Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of follistatin in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). Follistatin is a protein rather than a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About Follistatin</h4>Follistatin is a naturally occurring glycoprotein that binds activin with high affinity and regulates its biological activity. It also interacts with other members of the TGF-β superfamily and has been studied in connection with processes including muscle growth, reproduction, and tissue regulation.Follistatin occurs in several molecular forms and is widely used as a research target in studies of activin signalling and related biological pathways.<h4>Key Features</h4><ul><li>Targeted identification and quantification of follistatin</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powder</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Follistatin</li><li>Testing method: HPLC</li><li>Result format for lyophilisate: mg per vial</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for lyophilisate: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powder: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Follistatin is a protein rather than a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?search=Endotoxin">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

L-Carnitine analysis

Targeted HPLC analysis of L-carnitine in tablets, capsules, liquid samples, and raw API powders, confirming identity and determining content.

The L-Carnitine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of L-carnitine in oral dosage forms, liquid samples, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule, as well as liquid samples, with results reported in mg/ml. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About L-Carnitine</h4>L-carnitine is a naturally occurring compound involved in mitochondrial fatty-acid metabolism. Its primary biological role is to transport long-chain fatty acids across the inner mitochondrial membrane, enabling their subsequent beta-oxidation and use as a source of cellular energy.In the human body, L-carnitine is obtained from dietary sources and can also be synthesised endogenously from the amino acids lysine and methionine. It is concentrated particularly in tissues with high energy demands, such as skeletal and cardiac muscle, and is also used therapeutically in the management of primary and secondary carnitine deficiencies.<h4>Key Features</h4><ul><li>Targeted identification and quantification of L-carnitine</li><li>Suitable for tablets, capsules, liquid samples, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for liquid samples reported in mg/ml</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum liquid sample amount of 0.5–1 ml</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: L-Carnitine</li><li>CAS number: 541-15-1</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for liquid samples: mg/ml</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for liquid samples: 0.5–1 ml</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for L-carnitine. It does not automatically screen the sample for related carnitine derivatives, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>Purity reporting in % (m/m) is available as an alternative result format.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Lipo-C (L-Carnitine content, L-Arginine Content, B12 Content, Total Solids)

Lipo-C analysis determines L-carnitine, L-arginine, vitamin B12, and total solids content, with target compounds analysed by HPLC.

The Lipo-C Analysis is a targeted laboratory test designed to determine the content of L-carnitine, L-arginine, and vitamin B12, together with the total solids content of a Lipo-C sample.The target compounds are analysed by HPLC, with results reported in mg/ml. Total solids provide an additional measure of the overall amount of solid material present in the sample, helping assess the composition of the formulation beyond the individual quantified compounds.<h4>About the Analyzed Compounds</h4>L-carnitine is involved in mitochondrial fatty-acid metabolism and facilitates the transport of long-chain fatty acids into mitochondria for beta-oxidation. L-arginine is an amino acid involved in several metabolic pathways and serves as a precursor for nitric oxide synthesis.Vitamin B12 (cobalamin) is an essential micronutrient that functions as a cofactor for enzymes involved in important metabolic reactions and DNA synthesis.Total solids represent the overall solid material present in a sample, including dissolved and suspended material. This measurement complements the targeted determination of L-carnitine, L-arginine, and vitamin B12.<h4>Key Features</h4><ul><li>Targeted determination of L-carnitine, L-arginine, and vitamin B12</li><li>Total solids determination included</li><li>Analysis of target compounds by HPLC</li><li>Results reported in mg/ml</li><li>Suitable for Lipo-C liquid samples</li><li>Minimum sample amount of one whole unopened vial</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: L-Carnitine, L-Arginine, Vitamin B12</li><li>Additional determination: Total Solids</li><li>Testing method: HPLC</li><li>Result format: mg/ml</li><li>Minimum sample amount: One whole unopened vial</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically designed to determine L-carnitine, L-arginine, vitamin B12, and total solids in a Lipo-C sample.</li><li>The analysis does not automatically screen the sample for other active compounds, ingredients, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NAD+ analysis

Targeted HPLC analysis of NAD+ in tablets, capsules, and raw API powders, confirming compound identity and determining its amount.

The NAD+ Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of NAD+ in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). NAD+ is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About NAD+</h4>NAD+ (nicotinamide adenine dinucleotide) is the oxidized form of an essential cellular coenzyme involved in redox reactions and energy metabolism. It accepts electrons during metabolic reactions and is converted to its reduced form, NADH, which participates in cellular energy production.NAD+ is present throughout cellular metabolism and plays an important role in maintaining the balance between oxidation and reduction reactions required for normal cellular function.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NAD+</li><li>Suitable for tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: NAD+</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: m/m purity in % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NAD+ is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NAD+. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>The stated detection limit cutoff is less than 1/20 of the usual dosage per vial.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NMN (Nikotinamid mononukleotid) analysis

Targeted HPLC analysis of NMN in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The NMN Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of nicotinamide mononucleotide (NMN) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About NMN</h4>Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and an intermediate in the biosynthesis of nicotinamide adenine dinucleotide (<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2546">NAD+</a>). NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs).NAD+ is an essential cellular coenzyme involved in energy metabolism, redox reactions, and numerous enzymatic processes. NMN has therefore been studied as an NAD+ precursor in both preclinical and clinical research.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NMN</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Nicotinamide mononucleotide</li><li>Other name: NMN</li><li>CAS number: 1094-61-7</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NMN is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NMN. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Sibutramine analysis

Targeted HPLC analysis of sibutramine in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Sibutramine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sibutramine in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Sibutramine</h4>Sibutramine is a serotonin-noradrenaline reuptake inhibitor (SNRI) that was formerly used as a weight-management medicine. By inhibiting the reuptake of serotonin and noradrenaline, it affects neurotransmitter signalling involved in appetite and satiety.Sibutramine-containing medicines were suspended in the European Union and withdrawn from the U.S. market after clinical data showed an increased risk of serious cardiovascular events, including heart attack and stroke.<h4>Key Features</h4><ul><li>Targeted identification and quantification of sibutramine</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Sibutramine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 4 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for sibutramine. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of sibutramine required for evaluation is 4 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li><li>Laboratory confirmation of sibutramine content should not be interpreted as confirmation that a product is safe for human use.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

SLU-PP-332 analysis

Targeted HPLC analysis of SLU-PP-332 in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The SLU-PP-332 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of SLU-PP-332 in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised vials, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). SLU-PP-332 is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About SLU-PP-332</h4>SLU-PP-332 is a synthetic research compound that acts as an agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. These nuclear receptors regulate genes involved in mitochondrial metabolism, oxidative phosphorylation, and fatty-acid oxidation.SLU-PP-332 has been investigated primarily in preclinical studies. In mouse models, activation of ERR signalling by SLU-PP-332 has been associated with increased oxidative skeletal muscle fibres, improved exercise endurance, increased energy expenditure, and enhanced fatty-acid oxidation.<h4>Key Features</h4><ul><li>Targeted identification and quantification of SLU-PP-332</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: SLU-PP-332</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised vials: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised vials: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>SLU-PP-332 is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For lyophilised SLU-PP-332 samples, the standard testing procedure uses water (H₂O) as the solvent. However, SLU-PP-332 is poorly soluble in water, and insoluble material may therefore be filtered out before analysis. Only dissolved material can be analysed.</li><li>DMSO can be selected as an alternative solvent because it dissolves SLU-PP-332 more effectively. However, samples dissolved in DMSO are not suitable for injection or human use. To use DMSO for the analysis, select the DMSO solvent option from the additional services.</li><li>This analysis is specifically intended for SLU-PP-332. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Solvent: DMSO</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T3 analysis

Targeted HPLC analysis of T3 (liothyronine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T3 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T3 (liothyronine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T3</h4>T3, or triiodothyronine, is a naturally occurring thyroid hormone involved in the regulation of metabolism, growth, and energy utilisation. Liothyronine is the synthetic form of T3 used in pharmaceutical preparations.Liothyronine sodium is used clinically as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism. Cytomel is one of the established trade names for liothyronine sodium.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T3</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T3</li><li>Other names: Cytomel, Tiromel, liothyronine sodium</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T3. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T3 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T4 analysis

Targeted HPLC analysis of T4 (thyroxine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T4 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T4 (thyroxine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in micrograms per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T4</h4>T4, or thyroxine, is the major thyroid hormone produced and secreted by the thyroid gland. It plays an important role in the regulation of metabolism, growth, development, and energy utilisation. Much of circulating T4 is converted in peripheral tissues to the more biologically active thyroid hormone <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2550">T3</a>.Levothyroxine is the synthetic form of T4 and is widely used as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T4</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mcg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T4</li><li>Other name: Thyroxine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mcg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T4. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T4 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Tesofensine analysis

Targeted HPLC analysis of tesofensine in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The Tesofensine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of tesofensine in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised samples, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). Tesofensine is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About Tesofensine</h4>Tesofensine is a centrally acting monoamine reuptake inhibitor that inhibits the reuptake of serotonin, noradrenaline, and dopamine. Its effects on these neurotransmitter systems have been investigated primarily in relation to appetite regulation and body weight.<h4>Key Features</h4><ul><li>Targeted identification and quantification of tesofensine</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Tesofensine</li><li>CAS number: 195875-84-4</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised samples: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Tesofensine is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for tesofensine. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>For raw API powders, at least 30 mg should be supplied in a sealed glass vial to minimise moisture absorption.</li><li>Purity reporting in % (m/m) is available for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Products focused on HPLC - page 6

Related content

PFAS Analysis Beyond Water: Meeting the Challenges of Environmental, Food and Industrial Testing

ISC 2026 - Day 5

Wiley Launches Its First Spectral Analysis API Portfolio